Literature DB >> 28338116

How to Diagnose and Treat a Cancer of Unknown Primary Site.

Ciprian Tomuleasa1, Florin Zaharie2, Mihai-Stefan Muresan3, Laura Pop4, Zsolt Fekete5, Delia Dima6, Ioana Frinc7, Adrian Trifa8, Cristian Berce9, Ancuta Jurj4, Ioana Berindan-Neagoe4, Mihnea Zdrenghea7.   

Abstract

Almost one in every three patients with advanced tumors have distant metastasis at the time of clinical diagnosis. In most cases, the primary tumor site is identified immediately, within a few days. But for some patients, the primary lesion cannot be found after the initial clinical assessment. These cases are called cancers of unknown primary origin (CUPs), a clinical diagnosis very difficult to manage by physicians due to the absence of a standard-of-care for the initial therapeutic regimen, as well as due to the impossibility to include these cases in randomized clinical trials. A cancer of unknown primary site is often associated with a poor prognosis as patients are usually treated with a non-selective empirical therapy. In the current paper, we summarize both the diagnostic challenges for patients with a cancer of unknown primary site as well as the current available therapeutic options, with emphasis on the management of this unique disease entity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28338116     DOI: 10.15403/jgld.2014.1121.261.haz

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  12 in total

1.  Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor.

Authors:  Yoshihiro Hara; Kensuke Yamamura; Kazuki Matsumura; Eri Oda; Shinichi Akahoshi; Hideaki Yuki; Jun Tomiguchi; Toshihiko Motohara; Hideaki Miyamoto; Yoshihiko Komohara; Toru Beppu
Journal:  In Vivo       Date:  2021 Sep-Oct       Impact factor: 2.406

2.  Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study.

Authors:  Shigemasa Takamizawa; Tatsunori Shimoi; Masayuki Yoshida; Momoko Tokura; Shu Yazaki; Chiharu Mizoguchi; Ayumi Saito; Shosuke Kita; Kasumi Yamamoto; Yuki Kojima; Hitomi Sumiyoshi-Okuma; Tadaaki Nishikawa; Emi Noguchi; Kazuki Sudo; Kan Yonemori
Journal:  BMC Cancer       Date:  2022-04-14       Impact factor: 4.638

Review 3.  Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets.

Authors:  Annie Schmid-Alliana; Heidy Schmid-Antomarchi; Rasha Al-Sahlanee; Patricia Lagadec; Jean-Claude Scimeca; Elise Verron
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

Review 4.  Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.

Authors:  Alexandra Traila; Patriciu Achimas-Cadariu; Delia Dima; Romeo Micu
Journal:  Cancer Manag Res       Date:  2018-06-13       Impact factor: 3.989

Review 5.  Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.

Authors:  Antonella Argentiero; Antonio Giovanni Solimando; Oronzo Brunetti; Angela Calabrese; Francesco Pantano; Michele Iuliani; Daniele Santini; Nicola Silvestris; Angelo Vacca
Journal:  Cancers (Basel)       Date:  2019-08-29       Impact factor: 6.639

6.  Carcinoma of unknown primary abuts left clavicle: Case report and review of the literature.

Authors:  Georgios Geropoulos; Sofoklis Mitsos; Savvas Lampridis; Martin Hayward; Marco Scarci; Nikolaos Panagiotopoulos
Journal:  Int J Surg Case Rep       Date:  2019-12-19

Review 7.  Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site.

Authors:  Aisha Qaseem; Norina Usman; Joseph S Jayaraj; Rajesh Naidu Janapala; Tooba Kashif
Journal:  Cureus       Date:  2019-09-02

8.  Identification of Tumor Tissue of Origin with RNA-Seq Data and Using Gradient Boosting Strategy.

Authors:  Ruixi Li; Bo Liao; Bo Wang; Chan Dai; Xin Liang; Geng Tian; Fangxiang Wu
Journal:  Biomed Res Int       Date:  2021-02-17       Impact factor: 3.411

9.  Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.

Authors:  Yen-Yun Wang; Huan-Da Chen; Steven Lo; Yuk-Kwan Chen; Yu-Ci Huang; Stephen Chu-Sung Hu; Ya-Ching Hsieh; Amos C Hung; Ming-Feng Hou; Shyng-Shiou F Yuan
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.639

10.  Pineal Gland Metastasis From Poorly Differentiated Carcinoma of Unknown Primary Origin.

Authors:  Joshua A Cuoco; Michael W Kortz; Michael J Benko; Robert W Jarrett; Cara M Rogers; Mark R Witcher; Eric A Marvin
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-23       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.